Entities tied to Luke Evnin sell HOWL shares
Werewolf Therapeutics, Inc. reported an insider transaction involving entities associated with director Luke Evnin.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Werewolf Therapeutics, Inc. reported an insider transaction involving entities associated with director Luke Evnin. These entities executed an open-market sale of 76,928 shares of common stock at a weighted average price of $0.37 per share, pursuant to a pre-established Rule 10b5-1 trading plan dated March 26, 2026.
The shares were sold across several MPM-affiliated investment entities and, following the transaction, those entities collectively held 300,283 shares of Werewolf Therapeutics common stock. Evnin reports these holdings indirectly and disclaims beneficial ownership except to the extent of his pecuniary interest.
Insider Trade Summary 10b5-1
Net Seller: 76,928 shares
Net Sell
1 txn
Insider
EVNIN LUKE
Role
Director
Sold
76,928 shs ($28K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 76,928 | $0.37 | $28K |
Holdings After Transaction:
Common Stock — 300,283 shares (Indirect, See Footnotes)
Footnotes (5)
- F1. Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
- F2. The shares were sold as follows: 8,242 by MPM Asset Management LLC ("AM LLC"), 52,039 by MPM BioVentures 2014, L.P. ("BV 2014"), 3,471 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 1,791 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 11,385 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3553 to $0.3851 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- F5. The shares are held as follows: 32,171 by AM LLC, 203,135 by BV 2014, 13,546 by BV 2014(B), 6,989 by AM BV2014 and 44,442 by MPM OIF.
Key Figures
Shares sold: 76,928 shares
Average sale price: $0.37 per share
Post-transaction holdings: 300,283 shares
+5 more
8 metrics
Shares sold
76,928 shares
Open-market sale on June 9, 2026
Average sale price
$0.37 per share
Weighted average price for reported sale
Post-transaction holdings
300,283 shares
Indirectly held by associated entities after sale
Price range of trades
$0.3553–$0.3851
Range of individual trade prices in sale
Shares sold by BV 2014
52,039 shares
Portion of total sold by MPM BioVentures 2014, L.P.
Shares held by BV 2014
203,135 shares
Indirect holdings after transaction
Shares sold by AM LLC
8,242 shares
Portion of total sold by MPM Asset Management LLC
Shares held by AM LLC
32,171 shares
Indirect holdings after transaction
Key Terms
Rule 10b5-1, weighted average price, beneficial ownership, pecuniary interest, +2 more
6 terms
Rule 10b5-1 regulatory
"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026."
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein."
general partner financial
"MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC are the direct and indirect general partners of BV 2014 and BV 2014(B)."
A general partner is the person or firm that runs an investment partnership and legally represents it — they make the day-to-day decisions, choose which assets to buy or sell, and are responsible for the partnership’s obligations. Investors care because the general partner’s judgment, risk-taking and fee and profit-sharing arrangements determine both the potential returns and the level of exposure to losses; think of the GP as the ship’s captain whose skill and honesty shape the voyage’s outcome.
indirect ownership financial
"The shares are held as follows: 32,171 by AM LLC, 203,135 by BV 2014..."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Werewolf Therapeutics (HOWL) disclose for Luke Evnin?
Werewolf Therapeutics disclosed an insider transaction where entities associated with director Luke Evnin sold 76,928 shares of common stock. The sale was executed in the open market under a pre-established Rule 10b5-1 trading plan and reported as indirect ownership.
Were Luke Evnin’s Werewolf Therapeutics (HOWL) sales made under a Rule 10b5-1 plan?
Yes. The filing states the transaction was effected under a Rule 10b5-1 trading plan dated March 26, 2026. Such plans are pre-arranged and designed to allow insiders to sell shares on a predetermined schedule, reducing discretion over trade timing.
How are Luke Evnin’s indirect Werewolf Therapeutics (HOWL) holdings structured?
The filing explains that shares are held by multiple MPM-related entities, including AM LLC, BV 2014, BV 2014(B), AM BV2014, and MPM OIF. General partner and manager entities oversee these funds, and Evnin disclaims beneficial ownership beyond his pecuniary interest in them.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates